Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Aphria Inc. APHA

Aphria, which is headquartered in Ontario, produces and sells medicinal and recreational cannabis. The company operates through retail and wholesale channels in Canada and internationally. Aphria is a main distributor of medical cannabis to Germany and has operations in over 10 countries outside of Canada. However, it does not have exposure to the U.S. CBD or THC markets due to the constraints of federal prohibition. It has some U.S. exposure through the acquisition of SweetWater, a craft brewer


NDAQ:APHA - Post by User

Comment by IrishCanuckon Feb 04, 2021 10:39am
153 Views
Post# 32469899

RE:RE:Tilray enters 17th country - Spain

RE:RE:Tilray enters 17th country - SpainI can't tell you about volume. I'll include a little bit of Tilray's Q3 earnings transcript with a reminder how Aphria is growing to grow the weed for less than $0.79 per gram in the future. Imagine the margins on all the countries Tilray is getting into :)

Our average net selling price per gram of cannabis in Q3 2020 was $6.15, an 89.2% increase or $2.90 from the $3.25 during the same period in 2019 and a 133% increase from our reported selling price of $2.64 in Q2 of this year. As you may recall, we had a one-time transaction in Q2 related to the settlement of a supply contract with outlook, our reported selling price would have been $5.03. Compared to the normalized figure, the Q3 net selling price per gram increased by 22.3%. The increased selling price during Q3 was due to a shift in distribution channels and product mix, including the continued growth of our International Medical business, a shift in sales to higher potency and higher priced products, and the continued growth of our 2.0 products in Canada, which did not exist in the same period last year.
 
Going forward, we expect our average selling price per gram to remain stable or increase over time as sales of International Medical cannabis continue to make up a larger percentage of our sales mix. While we remain optimistic on International Markets, given the recent resurgence of COVID-19 in European countries and the restrictions that are likely to follow, we are cautious about the potential impacts and are taking whatever measures possible to ensure the uninterrupted supply of product to our distributors and patients. Our average cost per gram of cannabis sold in Q3 2020 was $4.23 per gram, an 85.5% increase from $2.28 during the same period in 2019 and $2.06 during the Q2 of this year. Please recall, the cost per gram in Q2 of this year was skewed by a onetime bulk transaction associated with the settlement of a supply contract.
<< Previous
Bullboard Posts
Next >>